1. Home
  2. Directory
  3. Florida
  4. Orlando
  5. Pain Medicine
  6. NPI Profile
  7. Prescriptions 1396024949

DR. GILBERT OCHIENG MBEO M.D.
Prescription History 1396024949
Pain Medicine - Interventional Pain Medicine in Orlando, FL

NPI Status: Active since August 15, 2011

Contact Information

13563 NARCOOSSEE RD STE 110
ORLANDO, FL
ZIP 32832
Phone: (407) 730-4240
Fax: (407) 887-1025

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for DR. GILBERT OCHIENG MBEO M.D., an active Interventional Pain Medicine specialist practicing in Orlando, FL. Our medical registry currently tracks 4 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 83 documented patient claims. Among these therapy options, the most frequently utilized medication is Meloxicam, which accounts for 39 claims alone.

Medication Index

C
G
M
P
No matching medications currently found on file.

Carbidopa-Levodopa

Generic Formulation: Carbidopa/LevodopaSpecialty: Neurology
Provider Metrics Summary
Total Claims 11
30-Day Fills 13.0
Days Supply 390
FL State Average Benchmarks
Peer Average Claims61.0
Peer Average 30-Day Fills112.2
Peer Average Days Supply3,281
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 82.0% less volume than the regional standard for practitioners inside FL. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $186.81 across this reporting matrix range.

Provider Avg Cost Per Claim

$16.98

State Avg Cost Per Claim

$47.19

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This combination medication is used to treat symptoms of Parkinson's disease or Parkinson-like symptoms (such as shakiness, stiffness, difficulty moving). Parkinson's disease is thought to be caused by too little of a naturally occurring substance (dopamine) in the brain. Levodopa changes into dopamine in the brain, helping to control movement. Carbidopa prevents the breakdown of levodopa in the bloodstream so more levodopa can enter the brain. Carbidopa can also reduce some of levodopa's side effects such as nausea and vomiting.

Gabapentin

Generic Formulation: GabapentinSpecialty: Neurology
Provider Metrics Summary
Total Claims 18
30-Day Fills 26.0
Days Supply 780
FL State Average Benchmarks
Peer Average Claims103.0
Peer Average 30-Day Fills177.9
Peer Average Days Supply5,249
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 82.5% less volume than the regional standard for practitioners inside FL. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $434.63 across this reporting matrix range.

Provider Avg Cost Per Claim

$24.15

State Avg Cost Per Claim

$19.25

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A cyclohexane-gamma-aminobutyric acid derivative that is used for the treatment of PARTIAL SEIZURES; NEURALGIA; and RESTLESS LEGS SYNDROME.

Therapeutic Applications

Gabapentin is used with other medications to prevent and control seizures. It is also used to relieve nerve pain following shingles (a painful rash due to herpes zoster infection) in adults. Gabapentin is known as an anticonvulsant or antiepileptic drug.

Meloxicam

Generic Formulation: MeloxicamSpecialty: Neurology
Provider Metrics Summary
Total Claims 39
30-Day Fills 47.0
Days Supply 1,410
FL State Average Benchmarks
Peer Average Claims58.0
Peer Average 30-Day Fills96.4
Peer Average Days Supply2,813
Conservative Utilization

This provider writes prescriptions for this formulation 32.8% less frequently than the standard regional baseline metric for practitioners inside FL. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $436.19 across this reporting matrix range.

Provider Avg Cost Per Claim

$11.18

State Avg Cost Per Claim

$6.18

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A benzothiazine and thiazole derivative that acts as a NSAID and cyclooxygenase-2 (COX-2) inhibitor. It is used in the treatment of RHEUMATOID ARTHRITIS; OSTEOARTHRITIS; and ANKYLOSING SPONDYLITIS.

Therapeutic Applications

Meloxicam is used to help relieve moderate to severe pain. Meloxicam is known as a nonsteroidal anti-inflammatory drug (NSAID). It works by blocking your body's production of certain natural substances that cause inflammation. This effect helps to decrease swelling or pain.

Pregabalin

Generic Formulation: PregabalinSpecialty: Neurology
Provider Metrics Summary
Total Claims 15
30-Day Fills 17.0
Days Supply 510
FL State Average Benchmarks
Peer Average Claims50.0
Peer Average 30-Day Fills63.9
Peer Average Days Supply1,862
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 70.0% less volume than the regional standard for practitioners inside FL. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $335.02 across this reporting matrix range.

Provider Avg Cost Per Claim

$22.33

State Avg Cost Per Claim

$42.21

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A gamma-aminobutyric acid (GABA) derivative that functions as a CALCIUM CHANNEL BLOCKER and is used as an ANTICONVULSANT as well as an ANTI-ANXIETY AGENT. It is also used as an ANALGESIC in the treatment of NEUROPATHIC PAIN and FIBROMYALGIA.

Therapeutic Applications

This medication is used to treat pain caused by nerve damage due to diabetes, shingles (herpes zoster) infection, or spinal cord injury. This medication is also used to treat pain in people with fibromyalgia. It is also used with other medications to treat certain types of seizures (focal seizures).

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like DR. GILBERT OCHIENG MBEO M.D. provides transparency into local medical care patterns within Orlando, FL.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Interventional Pain Medicine** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.